topotecan has been researched along with Anemia in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 13 (61.90) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agelaki, S; Bompolaki, I; Chandrinos, V; Georgoulias, V; Kalbakis, K; Kontopodis, E; Kotsakis, A; Papadimitraki, E; Stoltidis, D; Zafeiriou, Z | 1 |
| Bender, DP; Carter, JS; Dawson, D; Deng, W; Gray, HJ; Guaglianone, PP; Kunos, C; Lea, JS; Moore, KN; Zanotti, KM | 1 |
| Bodnar, L; Gasowska-Bodnar, A; Nasilowska, A; Smoter, M; Szarlej-Wcislo, K; Szczylik, C; Wcislo, G | 1 |
| Borad, MJ; Curtis, KK; Fitch, TR; Griffin, PP; Hartney, JT; Jewell, RC; Lebowitz, PF; Northfelt, DW; Park, JW | 1 |
| Billups, CA; Brennan, R; Free, TM; Given, V; Haik, BG; Helton, K; McCarville, MB; Merchant, TE; Qaddoumi, I; Rodriguez-Galindo, C; Stewart, CF; Tagen, M; Wilson, MW; Wu, J | 1 |
| DeBernardo, RL; Eaton, SM; Frasure, HE; Fusco, NL; Heugel, AM; Smith, DA; von Gruenigen, VE; Waggoner, SE | 1 |
| Adams, JR; Armitage, JO; Bennett, CL; Demetri, GD; Elting, LS; George, JN; Lembersky, BC; Lyman, GH | 1 |
| Belani, CP; Day, R; Jacobs, SA; Jett, JR; Ramalingam, S; Zamboni, BA | 1 |
| Ambaum, B; Beijnen, JH; Groenewegen, G; Herben, VM; Jansen, S; Kerbusch, T; Mathôt, RA; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Voest, EE | 1 |
| Cromwell, LD; Fadul, CE; Kingman, LS; McDonnell, CE; Meyer, LP; Pipas, JM; Rhodes, CH; Rigas, JR | 1 |
| Brunetti, C; Cassano, G; Colucci, G; Galetta, D; Gebbia, V; Germano, D; Giampaglia, M; Guida, M; Izzi, G; Lorusso, V; Nettis, G; Silvestris, N; Spada, M | 1 |
| Gajra, A; Garziano, S; Kirshner, J; Neuman, N; Perry, M; Ready, N; Shah, C | 1 |
| Robert, F; Soong, SJ; Wheeler, RH | 1 |
| Benedetti, JK; Macdonald, JS; Natale, RB; O'Rourke, MA; Wall, JG | 1 |
| Beijnen, JH; Herben, VM; Hudson, I; Schot, ME; ten Bokkel Huinink, WW | 1 |
| Anderson, H; Carrington, B; Cheeseman, S; Hearn, S; Ranson, M; Ross, G; Thatcher, N; White, SC | 1 |
| Fleming, GF; Janisch, L; Ratain, MJ; Ryan, CW | 1 |
| Blessing, JA; Kilgore, LC; Mannel, R; Miller, DS; Van Le, L | 1 |
| Conlon, KC; Curti, BD; Gause, BL; Janik, JE; Korn, EL; Longo, DL; Miller, LL; Sharfman, W; Smith, JW; Stevens, D; Sznol, M; Urba, WJ | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Palamidas, P; Raptis, A | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Souglakos, J; Vamvakas, L; Vardakis, N | 1 |
20 trial(s) available for topotecan and Anemia
| Article | Year |
|---|---|
A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Palliative Care; Small Cell Lung Carcinoma; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan | 2013 |
A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma; Cell Cycle Proteins; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Polyethylene Glycols; Recombinant Proteins; Ribonucleotide Reductases; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms | 2015 |
Salvage therapy with topotecan in heavily pretreated ovarian cancer patients.
Topics: Alopecia; Anemia; Antineoplastic Agents; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Multivariate Analysis; Nausea; Neutropenia; Ovarian Neoplasms; Salvage Therapy; Survival Analysis; Topotecan; Treatment Outcome; Vomiting | 2009 |
A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Biological Availability; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Fatigue; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan | 2010 |
Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Male; Neutropenia; Retinal Neoplasms; Retinoblastoma; Survival Rate; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan; Vincristine | 2012 |
Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Cohort Studies; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Uterine Neoplasms | 2012 |
Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Topotecan | 2004 |
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Interactions; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan | 2004 |
A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Filgrastim; Glioblastoma; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Recombinant Proteins; Thrombocytopenia; Topotecan; Treatment Outcome | 2005 |
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Platinum; Thrombocytopenia; Topotecan; Treatment Outcome | 2005 |
A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan; Vomiting | 2007 |
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Quality of Life; Remission Induction; Survival Analysis; Topotecan | 1997 |
Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Carcinoma, Hepatocellular; Enzyme Inhibitors; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan | 1997 |
Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Biomarkers; Carcinoma, Small Cell; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Thrombocytopenia; Topotecan; Treatment Outcome; Vomiting | 1998 |
Phase II study of oral topotecan in advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Thrombocytopenia; Topotecan; Treatment Outcome; Vomiting | 2000 |
A phase I study of liposomal doxorubicin (Doxil) with topotecan.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan | 2000 |
Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Cohort Studies; Disease Progression; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Leiomyosarcoma; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Remission Induction; Thrombocytopenia; Topotecan; Uterine Neoplasms | 2000 |
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
Topics: Anemia; Antineoplastic Agents; Carcinoma, Renal Cell; Diabetes Mellitus, Type 1; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypotension; Kidney Neoplasms; Melanoma; Neutropenia; Premedication; Prospective Studies; Remission Induction; Severity of Illness Index; Skin Neoplasms; Stroke; Thrombocytopenia; Topotecan; Treatment Outcome | 2001 |
A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topotecan | 2001 |
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms | 2001 |
1 other study(ies) available for topotecan and Anemia
| Article | Year |
|---|---|
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.
Topics: Anemia; Antineoplastic Agents; Confidence Intervals; Cost Savings; Cross-Cultural Comparison; Drug Utilization; Erythropoietin; Fee-for-Service Plans; Female; Health Expenditures; Hemoglobinometry; Humans; Male; Managed Care Programs; Medical Oncology; Neoplasms; Odds Ratio; Ovarian Neoplasms; Practice Guidelines as Topic; Practice Patterns, Physicians'; Regression Analysis; Topotecan; United States | 2004 |